oral glp 1 pfizer to discontinue danuglipron, its GLP-1 pill for obesity| STAT Are Pills the Next Big

Pfizer's decision to halt development of the drug came after "a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators," according to a release

Detailed data from the study are expected to be presented at an upcoming international medical meeting and submitted for publication in a peer-reviewed journal

GLP-1 receptor agonists (GLP-1RAs) have the potential to reduce these risk factors, but their role in lymphedema has never been investigated

Studies exclusively evaluating supraphysiologic androgen dosing, anabolic steroid misuse, or performance enhancement in eugonadal athletes were excluded